Luis G BermÃºdez-HumarÃ¡n

List of Publications by Year
in descending order

143 papers	13,782 citations	31976 53 h-index	22166 113 g-index
156 all docs	156 docs citations	156 times ranked	15300 citing authors

#	Article	IF	Citations
1	Genome Sequence and Assessment of Safety and Potential Probiotic Traits of Lactobacillus johnsonii CNCM I-4884. Microorganisms, 2022, 10, 273.	3.6	8
2	Looking inside Mexican Traditional Food as Sources of Synbiotics for Developing Novel Functional Products. Fermentation, 2022, 8, 123.	3.0	7
3	Functional characterization of Î±-Gal producing lactic acid bacteria with potential probiotic properties. Scientific Reports, 2022, 12, 7484.	3.3	8
4	Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti). Frontiers in Immunology, 2022, 13, .	4.8	5
5	Functional Foods, Nutraceuticals and Probiotics: A Focus on Human Health. Microorganisms, 2022, 10, 1065.	3.6	48
6	Effects of a Modern Kefir on Conditions Associated with Moderate Severe Spastic Quadriparesis Cerebral Palsy. Microorganisms, 2022, 10, 1291.	3.6	2
7	Strategies for the Identification and Assessment of Bacterial Strains with Specific Probiotic Traits. Microorganisms, 2022, 10, 1389.	3.6	6
8	Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis. Cellular and Molecular Life Sciences, 2021, 78, 1191-1206.	5.4	27
9	The Administration Matrix Modifies the Beneficial Properties of a Probiotic Mix of Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus acidophilus LA-5. Probiotics and Antimicrobial Proteins, 2021, 13, 484-494.	3.9	11
10	Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response. Gut Microbes, 2021, 13, 1-17.	9.8	48
11	Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease. Vaccines, 2021, 9, 466.	4.4	30
12	Antioxidant and Anti-Inflammatory Properties of Probiotic Candidate Strains Isolated during Fermentation of Agave (Agave angustifolia Haw). Microorganisms, 2021, 9, 1063.	3.6	13
13	Role of Gut Microbiota and Probiotics in Colorectal Cancer: Onset and Progression. Microorganisms, 2021, 9, 1021.	3.6	34
14	Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium. Microorganisms, 2021, 9, 1634.	3.6	17
15	Age and Giardia intestinalis Infection Impact Canine Gut Microbiota. Microorganisms, 2021, 9, 1862.	3.6	10
16	Probiotics and Trained Immunity. Biomolecules, 2021, 11, 1402.	4.0	17
17	Probiotics against Viral Infections: Current Clinical Trials and Future Perspectives. Immuno, 2021, 1, 468-498.	1.5	3
18	Probiotic Properties of Lactobacillus Strains Isolated from Table Olive Biofilms. Probiotics and Antimicrobial Proteins, 2020, 12, 1071-1082.	3.9	16

#	Article	IF	Citations
19	Butyrate mediates anti-inflammatory effects of <i>Faecalibacterium prausnitzii</i> in intestinal epithelial cells through <i>Dact3</i>. Gut Microbes, 2020, 12, 1826748.	9.8	90
20	Identification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35. Scientific Reports, 2020, 10, 17074.	3.3	9
21	Protective Effect of Glycomacropeptide on Food Allergy with Gastrointestinal Manifestations in a Rat Model through Down-Regulation of Type 2 Immune Response. Nutrients, 2020, 12, 2942.	4.1	12
22	Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains. Microorganisms, 2020, 8, 1053.	3.6	21
23	Gut Microbiota Abrogates Anti-Î±-Gal IgA Response in Lungs and Protects against Experimental Aspergillus Infection in Poultry. Vaccines, 2020, 8, 285.	4.4	26
24	Targeting Melanoma Hypoxia with the Food-Grade Lactic Acid Bacterium Lactococcus Lactis. Cancers, 2020, 12, 438.	3.7	13
25	Probiotics as Anti-Giardia Defenders: Overview on Putative Control Mechanisms. , 2020, , 335-349.		1
26	Oral delivery of pancreatitisâ€associated protein by <i>Lactococcus lactis</i> displays protective effects in dinitroâ€benzenesulfonicâ€acidâ€induced colitis model and is able to modulate the composition of the microbiota. Environmental Microbiology, 2019, 21, 4020-4031.	3.8	15
27	From Probiotics to Psychobiotics: Live Beneficial Bacteria Which Act on the Brain-Gut Axis. Nutrients, 2019, 11, 890.	4.1	99
28	The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response. Scientific Reports, 2019, 9, 5398.	3.3	98
29	Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity. FASEB Journal, 2019, 33, 4741-4754.	0.5	27
30	A New Bifidobacteria Expression SysTem (BEST) to Produce and Deliver Interleukin-10 in Bifidobacterium bifidum. Frontiers in Microbiology, 2018, 9, 3075.	3.5	23
31	M cellâ€"targeting strategy enhances systemic and mucosal immune responses induced by oral administration of nuclease-producing L. lactis. Applied Microbiology and Biotechnology, 2018, 102, 10703-10711.	3.6	12
32	Live bacterial biotherapeutics in the clinic. Nature Biotechnology, 2018, 36, 816-818.	17.5	17
33	Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?. , 2018, , 363-370.		0
34	Bile Salt Hydrolase Activities: A Novel Target to Screen Anti-Giardia Lactobacilli?. Frontiers in Microbiology, 2018, 9, 89.	3.5	38
35	Searching for the Bacterial Effector: The Example of the Multi-Skilled Commensal Bacterium Faecalibacterium prausnitzii. Frontiers in Microbiology, 2018, 9, 346.	3.5	84
36	A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain. Frontiers in Microbiology, 2018, 9, 565.	3.5	30

#	Article	IF	Citations
37	Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. Oncotarget, 2018, 9, 18224-18238.	1.8	90
38	Anti-tumoral Effects of Recombinant Lactococcus lactis Strain Secreting IL-17A Cytokine. Frontiers in Microbiology, 2018, 9, 3355.	3.5	28
39	Elucidating the Immune-Related Mechanisms by Which Probiotic Strain Lactobacillus casei BL23 Displays Anti-tumoral Properties. Frontiers in Microbiology, 2018, 9, 3281.	3.5	34
40	Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microbial Cell Factories, 2017, 16, 79.	4.0	581
41	Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model. International Immunopharmacology, 2017, 42, 122-129.	3.8	57
42	Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?. Microbiology Spectrum, 2017, 5, .	3.0	4
43	Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis. Microbial Cell Factories, 2017, 16, 27.	4.0	51
44	Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer. Frontiers in Immunology, 2017, 8, 1553.	4.8	156
45	Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis. Frontiers in Microbiology, 2017, 8, 800.	3.5	69
46	Functional Characterization of Novel Faecalibacterium prausnitzii Strains Isolated from Healthy Volunteers: A Step Forward in the Use of F. prausnitzii as a Next-Generation Probiotic. Frontiers in Microbiology, 2017, 8, 1226.	3.5	320
47	New Insights into the Diversity of the Genus Faecalibacterium. Frontiers in Microbiology, 2017, 8, 1790.	3.5	71
48	Contribution of sortase SrtA2 to Lactobacillus casei BL23 inhibition of Staphylococcus aureus internalization into bovine mammary epithelial cells. PLoS ONE, 2017, 12, e0174060.	2.5	14
49	Bile-Salt-Hydrolases from the Probiotic Strain Lactobacillus johnsonii La1 Mediate Anti-giardial Activity in Vitro and in Vivo. Frontiers in Microbiology, 2017, 8, 2707.	3.5	48
50	Gnotobiotic Rodents: An In Vivo Model for the Study of Microbeâ€"Microbe Interactions. Frontiers in Microbiology, 2016, 7, 409.	3.5	57
51	Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice. Frontiers in Microbiology, 2016, 7, 608.	3.5	50
52	A large scale inÂvitro screening of Streptococcus thermophilus strains revealed strains with a high anti-inflammatory potential. LWT - Food Science and Technology, 2016, 70, 78-87.	5.2	30
53	A new lactobacilli<i>in vivo</i>expression system for the production and delivery of heterologous proteins at mucosal surfaces. FEMS Microbiology Letters, 2016, 363, fnw117.	1.8	28
54	Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Scientific Reports, 2016, 6, 19399.	3.3	72

#	Article	IF	Citations
55	Identification of an anti-inflammatory protein from<i>Faecalibacterium prausnitzii</i>, a commensal bacterium deficient in Crohnâ€™s disease. Gut, 2016, 65, 415-425.	12.1	585
56	Expression of fibronectin binding protein A (FnBPA) from Staphylococcus aureus at the cell surface of Lactococcus lactis improves its immunomodulatory properties when used as protein delivery vector. Vaccine, 2016, 34, 1312-1318.	3.8	24
57	Identification of novel anti-inflammatory probiotic strains isolated from pulque. Applied Microbiology and Biotechnology, 2016, 100, 385-396.	3.6	54
58	Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis. Journal of Medical Microbiology, 2016, 65, 1038-1046.	1.8	17
59	The secreted l-arabinose isomerase displays anti-hyperglycemic effects in mice. Microbial Cell Factories, 2015, 14, 204.	4.0	12
60	Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model. Microbial Cell Factories, 2015, 14, 176.	4.0	19
61	Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models. Gastroenterology Research and Practice, 2015, 2015, 1-8.	1.5	55
62	Effect of iron on the probiotic properties of the vaginal isolate Lactobacillus jensenii CECT 4306. Microbiology (United Kingdom), 2015, 161, 708-718.	1.8	15
63	Identification of Metabolic Signatures Linked to Anti-Inflammatory Effects of Faecalibacterium prausnitzii. MBio, 2015, 6, .	4.1	206
64	Intranasal administration with recombinant Lactococcus lactis expressing heme oxygenase-1 reduces hyperoxia-induced lung inflammation in rat pups. Biotechnology Letters, 2015, 37, 1203-1211.	2.2	5
65	Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiology, 2015, 15, 67.	3.3	208
66	Serine protease inhibitors protect better than IL-10 and TGF-Î² anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microbial Cell Factories, 2015, 14, 26.	4.0	103
67	<i>Lactobacillus rhamnosus</i>CNCM I-3690 and the commensal bacterium<i>Faecalibacterium prausnitzii</i>A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes, 2015, 6, 1-9.	9.8	143
68	Drying process strongly affects probiotics viability and functionalities. Journal of Biotechnology, 2015, 214, 17-26.	3.8	80
69	Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model. Current Pharmaceutical Biotechnology, 2015, 16, 424-429.	1.6	28
70	The Indigenous Microbiota and its Potential to Exhibit Probiotic Properties. , 2015, , 181-194.		0
71	Effects in the use of a genetically engineered strain of<i>Lactococcus lactis</i>delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. Human Vaccines and Immunotherapeutics, 2014, 10, 1611-1621.	3.3	65
72	The role of metagenomics in understanding the human microbiome in health and disease. Virulence, 2014, 5, 413-423.	4.4	87

#	Article	IF	Citations
73	Protective Effects of Lactococci Strains Delivering Either IL-10 Protein or cDNA in a TNBS-induced Chronic Colitis Model. Journal of Clinical Gastroenterology, 2014, 48, S12-S17.	2.2	35
74	Genetically Engineered Immunomodulatory Streptococcus thermophilus Strains Producing Antioxidant Enzymes Exhibit Enhanced Anti-Inflammatory Activities. Applied and Environmental Microbiology, 2014, 80, 869-877.	3.1	85
75	The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models. Inflammatory Bowel Diseases, 2014, 20, 417-430.	1.9	204
76	The Dual Role of MAPK Pathway in the Regulation of Intestinal Barrier. Inflammatory Bowel Diseases, 2014, 20, E17-E18.	1.9	6
77	Ecology and metabolism of the beneficial intestinal commensal bacterium<i>Faecalibacterium prausnitzii</i>. Gut Microbes, 2014, 5, 146-151.	9.8	128
78	Tu1778 Faecalibacterium prausnitzii Prevents Irritable Bowel Syndrome-Like Symptoms in Both Murine Low Grade Chronic Inflammation and Acute Stress Models. Gastroenterology, 2014, 146, S-840-S-841.	1.3	0
79	Tu1746 Faecalibacterium prausnitzii Provides Host Beneficial Metabolic Profile During Inflammation. Gastroenterology, 2014, 146, S-832.	1.3	0
80	Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders. American Journal of Gastroenterology, 2014, 109, 748-756.	0.4	56
81	83 Identification of an Anti-Inflammatory Protein From Faecalibacterium prausnitzii, a Deficient Commensal Bacteria Implicated in Crohn's Disease. Gastroenterology, 2014, 146, S-23.	1.3	0
82	Gut ecosystem: how microbes help us. Beneficial Microbes, 2014, 5, 219-233.	2.4	32
83	<scp>N</scp>uclease <scp>A</scp> (<scp>Gbs</scp>0661), an extracellular nuclease of <i><scp>S</scp>treptococcus agalactiae</i>, attacks the neutrophil extracellular traps and is needed for full virulence. Molecular Microbiology, 2013, 89, 518-531.	2.5	89
84	Engineering lactococci and lactobacilli for human health. Current Opinion in Microbiology, 2013, 16, 278-283.	5.1	148
85	Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease. Microbial Cell Factories, 2013, 12, 71.	4.0	188
86	Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Applied Microbiology and Biotechnology, 2013, 97, 1231-1239.	3.6	50
87	Tu1988 Impact of the Commensal Bacterium Faecalibacterium prausnitzii in a Non Active Inflammation Murine Model. Gastroenterology, 2013, 144, S-897-S-898.	1.3	1
88	Faecalibacterium prausnitzii and human intestinal health. Current Opinion in Microbiology, 2013, 16, 255-261.	5.1	829
89	Implications of the human microbiome in inflammatory bowel diseases. FEMS Microbiology Letters, 2013, 342, 10-17.	1.8	50
90	Identification of One Novel Candidate Probiotic Lactobacillus plantarum Strain Active against Influenza Virus Infection in Mice by a Large-Scale Screening. Applied and Environmental Microbiology, 2013, 79, 1491-1499.	3.1	92

#	Article	IF	Citations
91	Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiology Letters, 2013, 344, 1-9.	1.8	73
92	Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. Journal of Biotechnology, 2013, 168, 120-129.	3.8	93
93	Inactivation of the <i>ybdD</i> Gene in Lactococcus lactis Increases the Amounts of Exported Proteins. Applied and Environmental Microbiology, 2012, 78, 7148-7151.	3.1	4
94	Functional Analysis of the Lactobacillus casei BL23 Sortases. Applied and Environmental Microbiology, 2012, 78, 8684-8693.	3.1	55
95	Importance of Commensal and Probiotic Bacteria in Human Health. Current Immunology Reviews, 2012, 8, 248-253.	1.2	6
96	Mo1855 Oral Treatment With Elafin-Recombinant Probiotics Improves Visceral Pain and Hypersensitivity in a Model of Irritable Bowel Syndrome (IBS). Gastroenterology, 2012, 142, S-700-S-701.	1.3	0
97	Sa2060 Gnotobiotic Mice, a Promising Tool to Better Understand the Anti-Inflammatory Effects of Faecalibacterium prausnitziÃ¯?. Gastroenterology, 2012, 142, S-392.	1.3	1
98	Mo2015 Food-Grade Lactic Acid Bacteria Expressing Elastase Inhibitors Protect From Intestinal Inflammation in Acute and Chronic Models of Colitis in Mice. Gastroenterology, 2012, 142, S-720.	1.3	0
99	Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis. Science Translational Medicine, 2012, 4, 158ra144.	12.4	198
100	Sa2061 Protective and Curative Effect of Faecalibacterium prausnitzii in a Chronic DNBS-Induced Murine Colitis. Gastroenterology, 2012, 142, S-392.	1.3	3
101	Tu1842 Elastolytic Balance in IBD: the Elastase Inhibitor Elafin Prevents Loss of Barrier Function and Cytokines Release by Human Intestinal Epithelial Cells in IBD Conditions. Gastroenterology, 2012, 142, S-859.	1.3	0
102	Anti-inflammatory properties of dairy lactobacilli. Inflammatory Bowel Diseases, 2012, 18, 657-666.	1.9	68
103	Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against Rhodococcus equi infection. Vaccine, 2011, 30, 95-102.	3.8	23
104	Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microbial Cell Factories, 2011, 10, S4.	4.0	180
105	Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Molecular Medicine, 2011, 3, 559-572.	6.9	694
106	Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. Journal of Biotechnology, 2011, 151, 287-293.	3.8	141
107	Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. International Journal of Food Microbiology, 2010, 144, 35-41.	4.7	117
108	Variations of N-acetylation level of peptidoglycan do not influence persistence of Lactococcus lactis in the gastrointestinal tract. International Journal of Food Microbiology, 2010, 144, 29-34.	4.7	6

#	Article	IF	Citations
109	Perspectives for the development of human papillomavirus vaccines and immunotherapy. Expert Review of Vaccines, 2010, 9, 35-44.	4.4	15
110	Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium. BMC Research Notes, 2009, 2, 167.	1.4	19
111	Protective Effects of a Heme Oxygenase-1-Secreting Lactococcus lactis on Mucosal Injury Induced by Hemorrhagic Shock in Rats. Journal of Surgical Research, 2009, 153, 39-45.	1.6	14
112	Allergy Therapy by Intranasal Administration with Recombinant <i>Lactococcus lactis</i> Producing Bovine β-Lactoglobulin. International Archives of Allergy and Immunology, 2009, 150, 25-31.	2.1	29
113	<i>Lactococcus lactis</i>as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin, 2009, 5, 264-267.	2.4	81
114	Development of Mucosal Vaccines Based on Lactic Acid Bacteria. , 2009, , 1099-1122.		2
115	Production of biological active murine IFN-ÃŽÂ³ by recombinant Lactococcus lactis. FEMS Microbiology Letters, 2008, 280, 144-149.	1.8	27
116	Intragastric administration with recombinant Lactococcus lactis producing heme oxygenase-1 prevents lipopolysaccharide-induced endotoxemia in rats. FEMS Microbiology Letters, 2008, 283, 62-68.	1.8	10
117	Production of biologically active CXC chemokines by Lactococcus lactis: Evaluation of its potential as a novel mucosal vaccine adjuvant. Vaccine, 2008, 26, 5778-5783.	3.8	16
118	<i>Lactococcus lactis,</i> an Efficient Cell Factory for Recombinant Protein Production and Secretion. Journal of Molecular Microbiology and Biotechnology, 2008, 14, 48-58.	1.0	214
119	<i>Faecalibacterium prausnitzii</i> is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16731-16736.	7.1	3,581
120	Current Prophylactic and Therapeutic Uses of a Recombinant <i>Lactococcus lactis</i> Strain Secreting Biologically Active Interleukin-12. Journal of Molecular Microbiology and Biotechnology, 2008, 14, 80-89.	1.0	11
121	Anti-inflammatory Properties of Lactic Acid Bacteria: Current Knowledge,Applications and Prospects. Anti-Infective Agents in Medicinal Chemistry, 2008, 7, 148-154.	0.6	10
122	Effects of Intranasal Administration of a Leptin-Secreting Lactococcus lactis Recombinant on Food Intake, Body Weight, and Immune Response of Mice. Applied and Environmental Microbiology, 2007, 73, 5300-5307.	3.1	33
123	Intranasal Coadministration of Live Lactococci Producing Interleukin-12 and a Major Cow's Milk Allergen Inhibits Allergic Reaction in Mice. Vaccine Journal, 2007, 14, 226-233.	3.1	43
124	Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine, 2007, 25, 6581-6588.	3.8	79
125	Antimicrobial Activity of Divercin RV41 Produced and Secreted by <i>Lactococcus lactis</i>. Journal of Molecular Microbiology and Biotechnology, 2007, 13, 259-263.	1.0	5
126	Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microbial Cell Factories, 2007, 6, 22.	4.0	109

#	Article	IF	Citations
127	Consumption of Camembert cheese stimulates commensal enterococci in healthy human intestinal microbiota. FEMS Microbiology Letters, 2007, 276, 189-192.	1.8	14
128	Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis. Microbial Cell Factories, 2006, 5, 14.	4.0	26
129	Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice. International Immunopharmacology, 2006, 6, 610-615.	3.8	38
130	Construction and characterization of a Lactococcus lactis strain deficient in intracellular ClpP and extracellular HtrA proteases. Microbiology (United Kingdom), 2006, 152, 2611-2618.	1.8	44
131	Improvement of bovine ÃŸ-lactoglobulin production and secretion by Lactococcus lactis. Brazilian Journal of Medical and Biological Research, 2005, 38, 353-359.	1.5	16
132	A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors. Journal of Immunology, 2005, 175, 7297-7302.	0.8	183
133	Protein secretion in Lactococcus lactis : an efficient way to increase the overall heterologous protein production. Microbial Cell Factories, 2005, 4, 2.	4.0	178
134	Cell-surface display of E7 antigen from human papillomavirus type-16 in<i>Lactococcus lactis</i>and in<i>Lactobacillus plantarum</i>using a new cell-wall anchor from lactobacilli. Journal of Drug Targeting, 2005, 13, 89-98.	4.4	78
135	An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. Journal of Medical Microbiology, 2004, 53, 427-433.	1.8	135
136	Controlled intra- or extracellular production of staphylococcal nuclease and ovine omega interferon in<i>Lactococcus lactis</i>. FEMS Microbiology Letters, 2003, 224, 307-313.	1.8	73
137	Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiology Letters, 2003, 229, 37-42.	1.8	74
138	Fusion to a Carrier Protein and a Synthetic Propeptide Enhances E7 HPV-16 Production and Secretion in Lactococcus lactis. Biotechnology Progress, 2003, 19, 1101-1104.	2.6	35
139	Intranasal Immunization with Recombinant<i>Lactococcus lactis</i>Secreting Murine Interleukin-12 Enhances Antigen-Specific Th1 Cytokine Production. Infection and Immunity, 2003, 71, 1887-1896.	2.2	119
140	Controlled Production of Stable Heterologous Proteins in <i>Lactococcus lactis</i>. Applied and Environmental Microbiology, 2002, 68, 3141-3146.	3.1	89
141	Production of Human Papillomavirus Type 16 E7 Protein in <i>Lactococcus lactis</i>. Applied and Environmental Microbiology, 2002, 68, 917-922.	3.1	116
142	Molecular sexing of monomorphic endangeredAra birds. The Journal of Experimental Zoology, 2002, 292, 677-680.	1.4	22
143	Loss of Restriction Site DdeI, used for Avian Molecular Sexing, in Oreophasis derbianus. Reproduction in Domestic Animals, 2002, 37, 321-323.	1.4	11